Genelux Investor Presentation Deck

Over $4 Billion in Transactions in Active Oncolytic Space CG ONCOLOGY With its recent IPO, Genelux joined the public markets as a Phase 3 company A maturing field with Amgen launching Imlygic in 2014 and Phase 3 companies (CG Oncology, Replimune, GNLX) working to validate its power and potential GENELUX Emerging Late-Stage Modality AMGEN Acquired BioVex ($1b) 2011 AMGEN FDA approved IMLYGICTM 2015 Pfizer Collaboration with Ill Bristol Myers Squibb Western Oncolytics License Agreement with PsiOxus ($936m) 2016 Boehringer Ingelheim Acquired ViraTherapeutics ($245m) Celgene AstraZeneca License Agreement with Omnis Pharmaceuticals Participated in Oncorus' $57m Series A 2017 abbvie Collaboration with Turnstone Biologics 2018 GENELUX Janssen Acquired Benevir ($140m) REGENERON Collaboration with Vyriad Replimune® Replimune completed a $225 million offering as well as $200M in non-dilutive debt financing Replimune® $100m IPO MERCK Acquired Viralytics ($394m) CG Oncology raises aggregate $225 million in Series E and crossover financing for clinical-stage uro-onc pipeline 2019 Takeda Collaboration/ License Agreement with Turnstone Biologics ($120m) Genelux enters the public markets raising $68.5M in the first half of 2023 AstraZeneca Collaboration/ License Agreement with Transgene astellas Collaboration/ License Agreement with KaliVir ($634m) 2020 KISSEI Collaboration/ License Agreement with CG Oncology ($140m) Daiichi-Sankyo Approval of Teserpaturev 2021 ONCOLOGY $120m Series E GENELUX $171.5m License agreement with Newsoara 2022 Roche Collaboration with Replimune GENELUX IPO 2023 Replimune® CG ONCOLOGY $225m Secondary $105m Crossover Round 8

View entire presentation